S3 Table. Clinical outcomes between the RR-CHOP group and the historical R-CHOP group

	RR-CHOP (n=72)	R-CHOP (n=72)	p-value
Interim response			0.042
Complete response	31 (43.1)	18 (25.0)	
Partial response	34 (47.2)	42 (58.3)	
Stable disease	1 (1.4)	0	
Progressive disease	0	3 (4.2)	
Treatment-related mortality	2 (2.8)	3 (4.2)	
Interim response of male patients			0.016
Complete response	21 (48.8)	9 (20.5)	
Partial response	17 (39.5)	29 (65.9)	
Stable disease	1 (2.3)	0	
Progressive disease	0	1 (2.3)	
Treatment-related mortality	2 (4.6)	3 (6.8)	
Final response			0.041
Complete response	43 (59.7)	34 (47.2)	
Partial response	7 (9.7)	18 (25.0)	
Stable disease	1 (1.4)	0	
Progressive disease	1 (1.4)	4 (5.6)	
Treatment-related mortality	3 (4.2)	4 (5.6)	
Final response of male patients			
Complete response	24 (55.8)	22 (50.0)	0.209
Partial response	4 (9.3)	10 (22.7)	
Stable disease	0	0	
Progressive disease	2 (2.3)	3 (6.8)	
Treatment-related mortality	3 (6.8)	4 (5.6)	

Values are presented as number (%). R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone; RR-CHOP, intensified the first cycle of rituximab plus eight cycles of cyclophosphamide, doxorubicin, vincristine, and prednisolone with rituximab.